Initial assessment of meptazinol in the treatment of the pain of myocardial infarction/unstable angina.
Meptazinol, a new analgesic agent, was used to treat chest pain in patients admitted to a coronary care unit with suspected myocardial infarction or unstable angina. A pilot study showed that meptazinol was effective in relieving pain in 15 out of 22 subjects. There were no adverse haemodynamic effects nor respiratory depression. Nausea and/or vomiting occurred with administration of the drug but as these symptoms may occur in patients with myocardial infarction who have not received any analgesia (Ingram et al., 1980), a cause and effect relationship cannot be inferred in this respect. The incidence of other side effects ascribed to meptazinol was low.
D000787:Angina Pectoris / Q000188:drug therapy*; D001381:Azepines / Q000627:therapeutic use*; D003501:Cyclizine / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008621:Meptazinol / Q000009:adverse effects / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000150:complications*; D010146:Pain / Q000188:drug therapy* / Q000209:etiology
D001381:Azepines; D008621:Meptazinol; D003501:Cyclizine